# Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

> **NCT01316185** · PHASE1 · TERMINATED · sponsor: **Eiger BioPharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Hepatitis D

## Interventions

- **DRUG:** EBP921

## Key facts

- **NCT ID:** NCT01316185
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** the enrollment was slow and never completed.
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316185, "Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01316185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*